Vera Therapeutics Statistics
Total Valuation
VERA has a market cap or net worth of $2.40 billion. The enterprise value is $2.07 billion.
Important Dates
The next estimated earnings date is Monday, November 11, 2024, before market open.
| Earnings Date | Nov 11, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
VERA has 54.83 million shares outstanding. The number of shares has increased by 42.08% in one year.
| Shares Outstanding | 54.83M |
| Shares Change (YoY) | +42.08% |
| Shares Change (QoQ) | +7.37% |
| Owned by Insiders (%) | 0.82% |
| Owned by Institutions (%) | 87.04% |
| Float | 40.22M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 7.33 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 21.43, with a Debt / Equity ratio of 0.16.
| Current Ratio | 21.43 |
| Quick Ratio | 20.98 |
| Debt / Equity | 0.16 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -20.16 |
Financial Efficiency
Return on equity (ROE) is -46.05% and return on invested capital (ROIC) is -26.58%.
| Return on Equity (ROE) | -46.05% |
| Return on Assets (ROA) | -24.74% |
| Return on Capital (ROIC) | -26.58% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.11M |
| Employee Count | 51 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, VERA has paid $1,000 in taxes.
| Income Tax | 1,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +320.54% in the last 52 weeks. The beta is 1.02, so VERA's price volatility has been similar to the market average.
| Beta (5Y) | 1.02 |
| 52-Week Price Change | +320.54% |
| 50-Day Moving Average | 40.56 |
| 200-Day Moving Average | 39.43 |
| Relative Strength Index (RSI) | 55.91 |
| Average Volume (20 Days) | 947,917 |
Short Selling Information
The latest short interest is 6.19 million, so 11.29% of the outstanding shares have been sold short.
| Short Interest | 6.19M |
| Short Previous Month | 6.17M |
| Short % of Shares Out | 11.29% |
| Short % of Float | 15.39% |
| Short Ratio (days to cover) | 8.96 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -117.24M |
| Pretax Income | -107.85M |
| Net Income | -107.85M |
| EBITDA | n/a |
| EBIT | -117.24M |
| Earnings Per Share (EPS) | -$2.22 |
Full Income StatementBalance Sheet
The company has $384.39 million in cash and $52.83 million in debt, giving a net cash position of $331.55 million or $6.05 per share.
| Cash & Cash Equivalents | 384.39M |
| Total Debt | 52.83M |
| Net Cash | 331.55M |
| Net Cash Per Share | $6.05 |
| Equity (Book Value) | 327.87M |
| Book Value Per Share | 5.98 |
| Working Capital | 376.33M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$106.73 million and capital expenditures -$152,000, giving a free cash flow of -$106.88 million.
| Operating Cash Flow | -106.73M |
| Capital Expenditures | -152,000 |
| Free Cash Flow | -106.88M |
| FCF Per Share | -$1.95 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |